IGC Pharma, Inc. — Director's Dealing 2022

Jun 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: India Globalization Capital, Inc. (IGC)
CIK: 0001326205
Period of Report: 2022-03-21

Reporting Person: MUKUNDA RAM (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-21	Common Stock	M	333334	$0.0	Acquired	2508094	Direct
2022-05-31	Common Stock	M	600000	$0.0	Acquired	3108094	Direct
2022-06-01	Common Stock	M	200000	$0.0	Acquired	3308094	Direct
2022-03-21	Common Stock	M	16667	$0.0	Acquired	744084	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-21	Restricted Stock Units	$0.0	M	333334	Disposed		Common Stock (333334)	Direct
2022-05-31	Restricted Stock Units	$0.0	M	600000	Disposed	2032-03-31	Common Stock (600000)	Direct
2022-06-01	Restricted Stock Units	$0.0	M	200000	Disposed	2032-03-31	Common Stock (200000)	Direct
2022-03-21	Restricted Stock Units	$0.0	M	16667	Disposed		Common Stock (16667)	Indirect

Footnotes

F1: On July 19, 2021, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2022.

F2: On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached.